PALO ALTO, Calif., Jan. 8, 2024 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Hikma Pharmaceuticals PLC ("Hikma"), a multinational pharmaceutical company, today announced an agreement to promote Guardant Health's portfolio of liquid and tissue biopsy tests for cancer screening, recurrence monitoring and tumor mutation profiling for all solid cancers across the Middle East and North Africa (MENA). The partnership expands Guardant Health's global presence and in ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the addition of Terilyn Juarez Monroe as the company’s chief people officer, effective immediately. In the newly-created role, Monroe will lead the human resources function, including people operations; cultural and organizational transformation; talent acquisition; and diversity and inclusion initiatives. Amelia Merrill, who previously served as senior vice president of people, i ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that it has entered into a common stock purchase agreement with Baillie Gifford on behalf of accounts that it manages for the sale of 3,387,446 shares of its common stock in a registered direct offering at an offering price of $26.77 per share. Gross proceeds are approximately $90.7 million, before deducting expenses payable by Guardant Health. Guardant Health intends to use the n ...

Guardant Health, Inc. (NASDAQ:GH) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ET Company Participants Carrie Mendivil - IR Helmy Eltoukhy - Co-CEO AmirAli Talasaz - Co-CEO Michael Bell - CFO Conference Call Participants Tejas Savant - Morgan Stanley Dan Arias - Stifel Mark Massaro - BTIG Puneet Souda - Leerink Partners Kyle Mikson - Canaccord Genuity Jack Meehan - Nephron Research Dan Brennan - TD Cowen Patrick Donnelly - Citi Derik De Bruin - Bank of America Operator Hello, everyone, and welc ...

Blood Version 1 Version 2 CRC Sensitivity 84% 91% Study Results • Samples were run on both V1 and V2 tests ) GUARDANT Source: Guardant internal data Adding Shield to standard of care increases compliance meaningfully Randomized prospective study with Kaiser Permanente Center for Health Research ACG ** 2023 9 Shield V2 demonstrated improved clinical sensitivity relative to Shield V1 CRC Sensitivity N = 45 Specificity N = 1,458 84% (38/45) 91% Shield V1 – PMA device Shield V2 91% (41/45) 91% CRC Sensitivity N ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _____________________ FORM 10-Q _____________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 _____________________ GUARDANT HEALTH, INC. (Exact Name of Registrant as Sp ...

Guardant Health, Inc. (NASDAQ:GH) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Carrie Mendivil - IR Helmy Eltoukhy - Co-Founder, Co-CEO & Chairman AmirAli Talasaz - Co-CEO & Director Michael Bell - CFO Conference Call Participants Jack Meehan - Nephron Research Puneet Souda - Leerink Partners Patrick Donnelly - Citigroup David Delahunt - Goldman Sachs Group Daniel Leonard - Crédit Suisse Andrew Brackmann - William Blair & Company Sung Ji Nam - Scotiabank Operator Hello, ev ...

In light of the foregoing, investors are urged not to rely on any forward-looking statement or third-party data in reaching any conclusion or making any investment decision about any securities of the Company. High growth core business approaching breakeven with a potentially higher growth pipeline Growth in TissueNext, differentiated by our Lunit-powered Galaxy AI TECHNOLOGY LEADER Pipeline of multi-billion dollar revenue opportunities in early stages Spearheading a new patient-preferred category with Shie ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _____________________ FORM 10-Q _____________________ OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One) For the transition period from to ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38683 _____________________ For the quarterly period ended June 30, 2023 GUARDANT HEALTH, INC. (Exact Name of Registrant as Specifi ...

Guardant Health, Inc. (NASDAQ:GH) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants Alex Kleban - Vice President-Investor Relations Helmy Eltoukhy - Chairman & Co-Chief Executive Officer AmirAli Talasaz - Co-Chief Executive Officer Mike Bell - Chief Financial Officer Craig Eagle - Chief Medical Officer Conference Call Participants Dan Arias - Stifel Puneet Souda - SVB Securities Jack Meehan - Nephron Research Kyle Mikson - Canaccord Julia Qin - JPMorgan Dave Delahunt - Golden Sach ...